Table 2 Clinical and disease information
N = 683 | |
|---|---|
AR duration (years), mean ± SD | 10.8 ± 8.8 |
Etiologic allergen, N (%) | |
Dust mite | 199 (30.0) |
Pollen | 325 (48.9) |
Dust mite and pollen | 140 (21.1) |
Type of AR, N (%) | |
Intermittent | 200 (29.4) |
Persistent | 480 (70.6) |
ARIA Severity of AR, N (%) | |
Mild | 92 (13.5) |
Moderate/severe | 591 (86.5) |
VALERO severity of AR, N (%) | |
Mild | 92 (13.5) |
Moderate | 380 (55.6) |
Severe | 211 (30.9) |
Current pharmacological treatment, N (%) | |
No | 197 (28.8) |
Yes | 486 (71.2) |
Current allergen immunotherapy, N (%) | |
No | 159 (23.8) |
Yes | 508 (76.2) |
SCIT | 304 (60.7) |
SLIT | 194 (38.7) |
Both | 3 (0.6) |
Time from current AIT initiation (months), mean ± SD | 12.8 ± 14.2 |
Current use of medication versus before AIT initiation, N (%) | |
More medication | 10 (1.9) |
The same medication | 112 (20.7) |
Less medication | 418 (77.4) |
Current level of symptoms versus before AIT initiation, N (%) | |
More symptoms | 10 (1.9) |
The same level of symptoms | 92 (17.1) |
Less symptoms | 437 (81.1) |